Seeking Alpha

InterMune (ITMN -1.4%) sells its Actimmune interferon gamma-1b business to privately held Vidara...

InterMune (ITMN -1.4%) sells its Actimmune interferon gamma-1b business to privately held Vidara Therapeutics International for $55M in cash plus a two-year royalty stream. The company had stopped active development for Actimmune several years ago, preferring to focus its efforts on other R&D operations such as its Pirfenidone treatment for idiopathic pulmonary fibrosis.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|